Hypertriglyceridemia and delayed clearance of fat load in transgenic rabbits expressing human apolipoprotein CIII

Transgenic Research

Volumn 20, Issue 4, 2011, Pages 867-875

  Ding, Yinyuan ^a   Wang, Yuhui ^a   Zhu, Hong ^b   Fan, Jianglin ^c   Yu, Liqing ^d   Liu, George ^a   Liu, Enqi ^b  

^a Peking University   (China)

^b XI'AN JIAOTONG UNIVERSITY   (China)

^c UNIVERSITY OF YAMANASHI   (Japan)

^d WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Apolipoprotein CIII; Hypertriglyceridemia; Transgenic rabbit

Indexed keywords

APOLIPOPROTEIN C3; CHOLESTEROL; FAT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN LIPASE; TRIACYLGLYCEROL;

ANIMAL; ARTICLE; BLOOD; CORONARY ARTERY DISEASE; DISEASE MODEL; GENE EXPRESSION; GENETICS; HUMAN; HYPERTRIGLYCERIDEMIA; LIPID METABOLISM; LIVER; METABOLISM; RABBIT; TRANSGENIC ANIMAL;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; APOLIPOPROTEIN C-III; CHOLESTEROL; CHOLESTEROL, HDL; CORONARY DISEASE; DISEASE MODELS, ANIMAL; FATS; GENE EXPRESSION; HUMANS; HYPERTRIGLYCERIDEMIA; LIPID METABOLISM; LIPOPROTEIN LIPASE; LIVER; RABBITS; TRIGLYCERIDES;

MUS MUSCULUS; ORYCTOLAGUS CUNICULUS;

EID: 79960442664     PISSN: 09628819     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11248-010-9467-5     Document Type: Article

References (38)

1. Aalto-Setala K, Fisher EA, Chen X, Chajek-Shaul T, Hayek T, Zechner R, Walsh A, Ramakrishnan R, Ginsberg HN, Breslow JL (1992) Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles. J Clin Invest 90(5): 1889-1900.
2. Bobik A (2008) Apolipoprotein CIII and atherosclerosis: beyond effects on lipid metabolism. Circulation 118: 702-704.
3. Brewer HB Jr, Shulman R, Herbert P, Ronan R, Wehrly K (1974) The complete amino acid sequence of alanine apolipoprotein (apoC-3), and apolipoprotein from human plasma very low density lipoproteins. J Biol Chem 249(15): 4975-4984.
4. Brousseau ME, Kauffman RD, Herderick EE, Demosky SJ Jr, Evans W, Marcovina S, Santamarina-Fojo S, Brewer HB Jr, Hoeg JM (2000) LCAT modulates atherogenic plasma lipoproteins and the extent of atherosclerosis only in the presence of normal LDL receptors in transgenic rabbits. Arterioscler Thromb Vasc Biol 20: 450-458.
5. Cohn JS, Tremblay M, Batal R, Jacques H, Rodriguez C, Steiner G, Mamer O, Davignon J (2004a) Increased apoC-III production is a characteristic feature of patients with hypertriglyceridemia. Atherosclerosis 177(1): 137-145.
6. Cohn JS, Patterson BW, Uffelman KD, Davignon J, Steiner G (2004b) Rate of production of plasma and very-low-density lipoprotein (VLDL) apolipoprotein C-III is strongly related to the concentration and level of production of VLDL triglyceride in male subjects with different body weights and levels of insulin sensitivity. J Clin Endocrinol Metab 89(8): 3949-3955.
7. Couillard C, Vohl MC, Engert JC, Lemieux I, Houde A, Almeras N, Prud'homme D, Nadeau A, Despres JP, Bergeron J (2003) Effect of apoC-III gene polymorphisms on the lipoprotein-lipid profile of viscerally obese men. J Lipid Res 44(5): 986-993.
8. de Silva HV, Lauer SJ, Wang J, Simonet WS, Weisgraber KH, Mahley RW, Taylor JM (1994) Overexpression of human apolipoprotein C-III in transgenic mice results in an accumulation of apolipoprotein B48 remnants that is corrected by excess apolipoprotein E. J Biol Chem 269(3): 2324-2335.
9. Duivenvoorden I, Teusink B, Rensen PC, Romijn JA, Havekes LM, Voshol PJ (2005) Apolipoprotein C3 deficiency results in diet-induced obesity and aggravated insulin resistance in mice. Diabetes 54(3): 664-671.
10. Ebara T, Ramakrishnan R, Steiner G, Shachter NS (1997) Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E. J Clin Invest 99(11): 2672-2681.
11. Falko JM, Witztum JL, Schonfeld G, Bateman J (1979) Dietary treatment of type V hyperlipoproteinemia fails to normalize low levels of high-density lipoprotein cholesterol. Ann Intern Med 91(5): 750-751.
12. Fan J, Challah M, Watanabe T (1999) Transgenic rabbit models for biomedical research: current status, basic methods and future perspectives. Pathol Int 49(7): 583-594.
13. Fan J, Shimoyamada H, Sun H, Marcovina S, Honda K, Watanabe T (2001) Transgenic rabbits expressing human apolipoprotein(a) develop more extensive atherosclerotic lesions in response to a cholesterol-rich diet. Arterioscler Thromb Vasc Biol 21: 88-94.
14. Ginsberg HN, Le NA, Goldberg IJ, Gibson JC, Rubinstein A, Wang-Iverson P, Norum R, Brown WV (1986) Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. J Clin Invest 78(5): 1287-1295.
15. Hayek T, Azrolan N, Verdery RB, Walsh A, Chajek-Shaul T, Agellon LB, Tall AR, Breslow JL (1993) Hypertriglyceridemia and cholesteryl ester transfer protein interact to dramatically alter high density lipoprotein levels, particle sizes, and metabolism. Studies in transgenic mice. J Clin Invest 92(3): 1143-1152.
16. Huang W, Bi N, Zhang X, Wang Y, Chen B, Liu G (2006) Overexpression of apolipoprotein AV in the liver reduces plasma triglyceride and cholesterol but not HDL in ApoE deficient mice. Biochem Biophys Res Commun 346(1): 14-18.
17. Ito Y, Azrolan N, O'Connell A, Walsh A, Breslow JL (1990) Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice. Science 249(4970): 790-793.
18. Kawakami A, Yoshida M (2009) Apolipoprotein CIII links dyslipidemia with atherosclerosis. J Atheroscler Thromb 16(1): 6-11.
19. Kawakami A, Aikawa M, Alcaide P, Luscinskas FW, Libby P, Sacks FM (2006a) Apolipoprotein CIII induces expression of vascular cell adhesion molecule-1 in vascular endothelial cells and increases adhesion of monocytic cells. Circulation 114(7): 681-687.
20. Kawakami A, Aikawa M, Libby P, Alcaide P, Luscinskas FW, Sacks FM (2006b) Apolipoprotein CIII in apolipoprotein B lipoproteins enhances the adhesion of human monocytic cells to endothelial cells. Circulation 113(5): 691-700.
21. Kawakami A, Osaka M, Tani M, Azuma H, Sacks FM, Shimokado K, Yoshida M (2008) Apolipoprotein CIII links hyperlipidemia with vascular endothelial cell dysfunction. Circulation 118(7): 731-742.
22. Kinnunen PK, Ehnolm C (1976) Effect of serum and C-apoproteins from very low density lipoproteins on human postheparin plasma hepatic lipase. FEBS Lett 65(3): 354-357.
23. Kitajima S, Jin Y, Koike T, Yu Y, Liu E, Shiomi M, Marcovina SM, Morimoto M, Watanabe T, Fan J (2007) Lp(a) enhances coronary atherosclerosis in transgenic Watanabe heritable hyperlipidemic rabbits. Atherosclerosis 193: 269-276.
24. Koike T, Liang J, Wang X, Ichikawa T, Shiomi M, Sun H, Watanabe T, Liu G, Fan J (2005) Enhanced aortic atherosclerosis in transgenic Watanabe heritable hyperlipidemic rabbits expressing lipoprotein lipase. Cardiovasc Res 65: 524-534.
25. Koike T, Kitajima S, Yu Y, Li Y, Nishijima K, Liu E, Sun H, Waqar AB, Shibata N, Inoue T, Wang Y, Zhang B, Kobayashi J, Morimoto M, Saku K, Watanabe T, Fan J (2009a) Expression of human apoAII in transgenic rabbits leads to dyslipidemia: a new model for combined hyperlipidemia. Arterioscler Thromb Vasc Biol 29(12): 2047-2053.
26. Koike T, Kitajima S, Yu Y, Nishijima K, Zhang J, Ozaki Y, Morimoto M, Watanabe T, Bhakdi S, Asada Y, Chen YE, Fan J (2009b) Human C-reactive protein does not promote atherosclerosis in transgenic rabbits. Circulation 120: 2088-2094.
27. Lenich C, Brecher P, Makrides S, Chobanian A, Zannis VI (1988) Apolipoprotein gene expression in the rabbit: abundance, size, and distribution of apolipoprotein mRNA species in different tissues. J Lipid Res 29(6): 755-764.
28. McConathy WJ, Gesquiere JC, Bass H, Tartar A, Fruchart JC, Wang CS (1992) Inhibition of lipoprotein lipase activity by synthetic peptides of apolipoprotein C-III. J Lipid Res 33(7): 995-1003.
29. Ooi EM, Barrett PH, Chan DC, Watts GF (2008) Apolipoprotein C-III: understanding an emerging cardiovascular risk factor. Clin Sci (Lond) 114(10): 611-624.
30. Pollin TI, Damcott CM, Shen H, Ott SH, Shelton J, Horenstein RB, Post W, McLenithan JC, Bielak LF, Peyser PA, Mitchell BD, Miller M, O'Connell JR, Shuldiner AR (2008) A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science 322(5908): 1702-1705.
31. Recalde D, Baroukh N, Viglietta C, Prince S, Verona J, Vergnes L, Pidoux J, Nanjee MN, Brites F, Ochoa A, Castro G, Zakin MM, Miller NE, Houdebine LM (2004) Human apoA-I/C-III/A-IV gene cluster transgenic rabbits: effects of a high-cholesterol diet. FEBS Letters 572: 294-298.
32. Recillas-Targa F, Pikaart MJ, Burgess-Beusse B, Bell AC, Litt MD, West AG, Gaszner M, Felsenfeld G (2002) Position-effect protection and enhancer blocking by the chicken beta-globin insulator are separable activities. Proc Natl Acad Sci USA 99(10): 6883-6888.
33. Saidi Y, Sich D, Camproux A, Egloff M, Federspiel MC, Gautier V, Raisonnier A, Turpin G, Beucler I (1999) Interrelationships between postprandial lipoprotein B: CIII particle changes and high-density lipoprotein subpopulation profiles in mixed hyperlipoproteinemia. Metabolism 48(1): 60-67.
34. Salerno AG, Silva TR, Amaral ME, Alberici LC, Bonfleur ML, Patrício PR, Francesconi EP, Grassi-Kassisse DM, Vercesi AE, Boschero AC, Oliveira HC (2007) Overexpression of apolipoprotein CIII increases and CETP reverses diet-induced obesity in transgenic mice. Int J Obes (Lond) 31(10): 1586-1595.
35. van Eck M, Zimmermann R, Groot PH, Zechner R, van Berkel TJ (2000) Role of macrophage-derived lipoprotein lipase in lipoprotein metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol 20(9): E53-E62.
36. Vergnes L, Baroukh N, Ostos MA, Castro G, Duverger N, Nanjee MN, Najib J, Fruchart JC, Miller NE, Zakin MM, Ochoa A (2000) Induces hyperlipidemia but reduces atherogenesis expression of human apolipoprotein A-I/C-III/A-IV gene cluster in mice. Arterioscler Thromb Vasc Biol 20: 2267-2274.
37. Wang CS, McConathy WJ, Kloer HU, Alaupovic P (1985) Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III. J Clin Invest 75(2): 384-390.
38. Witztum JL, Dillingham MA, Giese W, Bateman J, Diekman C, Blaufuss EK, Weidman S, Schonfeld G (1980) Normalization on triglycerides in type IV hyperlipoproteinemia fails to correct low levels of high-density-lipoprotein cholesterol. N Engl J Med 303(16): 907-914.